Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study

David M Maahs; M. Luiza Caramori; David Z.I Cherney; Andrzej T Galecki; Chuanyun Gao; Diana Jalal; Bruce A Perkins; Rodica Pop-Busui; Peter Rossing; Michael Mauer; Alessandro Doria; PERL Consortium

doi:10.1007/s11892-013-0381-0

Back

Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study

Journal article

Peer reviewed

Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study

David M Maahs, M. Luiza Caramori, David Z.I Cherney, Andrzej T Galecki, Chuanyun Gao, Diana Jalal, Bruce A Perkins, Rodica Pop-Busui, Peter Rossing, Michael Mauer, …

Current diabetes reports, Vol.13(4), pp.550-559

08/2013

DOI: 10.1007/s11892-013-0381-0

PMCID: PMC3703487

PMID: 23649945

Files and links (1)

url

http://doi.org/10.1007/s11892-013-0381-0View

Open Access

Abstract

Diabetic kidney disease causes significant morbidity and mortality among people with type 1 diabetes (T1D). Intensive glucose and blood pressure control have thus far failed to adequately curb this problem and therefore a major need for novel treatment approaches exists. Multiple observations link serum uric acid levels to kidney disease development and progression in diabetes and strongly argue that uric acid lowering should be tested as one such novel intervention. A pilot of such a trial, using allopurinol, is currently being conducted by the Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial targets T1D individuals at highest risk of kidney function decline, the use of allopurinol as a renoprotective agent may also be relevant to a larger segment of the population with diabetes. As allopurinol is inexpensive and safe, it could be cost-effective even for relatively low-risk patients, pending the completion of appropriate trials at earlier stages.

diabetic kidney disease

type 1 diabetes

glomerular filtration rate

PERL trial

kidney disease

randomized clinical trial

allopurinol

uric acid

diabetes

diabetic nephropathy

Details

Title: Subtitle: Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study
Creators: David M Maahs - Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO
M. Luiza Caramori - Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN
David Z.I Cherney - Department of Medicine and Division of Nephrology, University of Toronto, Toronto, ON
Andrzej T Galecki - Division of Geriatrics/Institute of Gerontology, Medical School, and Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI
Chuanyun Gao - Joslin Clinic, Joslin Diabetes Center, Boston, MA
Diana Jalal - Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO
Bruce A Perkins - Department of Medicine and Division of Endocrinology, University of Toronto, Toronto, ON
Rodica Pop-Busui - Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI
Peter Rossing - Steno Diabetes Center, Gentofte, Denmark
Michael Mauer - Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN
Alessandro Doria - Research Division, Joslin Diabetes Center, Boston, MA
PERL Consortium
Resource Type: Journal article
Publication Details: Current diabetes reports, Vol.13(4), pp.550-559
DOI: 10.1007/s11892-013-0381-0
PMID: 23649945
PMCID: PMC3703487
NLM abbreviation: Curr Diab Rep
ISSN: 1534-4827
eISSN: 1539-0829
Language: English
Date published: 08/2013
Academic Unit: Nephrology; Internal Medicine
Record Identifier: 9984094655902771

Metrics

34 Record Views

119 Times Cited - Web of Science